BioNTech SE (BNTX) Stock Forecast & Price Target

BioNTech is expected to witness a decline in COVID revenues over the next few years due to decreased demand amidst the declining pandemic, with a 24% decline in FY26. However, the company's focus on advancing their oncology pipeline is expected to bring long-term benefits, with important data updates for their pumitamig and Ph3 pivotal studies for BNT323 expected in 2026. BioNTech's commercial and partnership risks include negative data for various drugs, slower market uptake, and possible dilution risk, but the company is still valued at $33B, with a projected price objective of $130 per share based on a DCF-based valuation approach and other parameters.

BioNTech is facing a number of fundamental risks, including potential competition from other biotechnology companies, particularly in the development of cancer therapeutics. Additionally, the small sample sizes and lack of detailed patient data for MK-2010 make it difficult to accurately compare its efficacy to other drugs, such as pumitamig. Furthermore, delay in the advancement of other programs and regulatory and commercial risks could significantly impact the company's revenue generation. While the interim Phase 3 data for gotistobart in 2L squamous NSCLC appears positive, there is no guarantee for approval, and potential safety or efficacy concerns could result in significant delays and impact future forecasts.